A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs AutoSynVax (Primary) ; QS 21
- Indications Cancer
- Focus Adverse reactions
- Sponsors Agenus
- 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to an Agenus Inc. media release.
- 04 May 2017 According to an Agenus Inc. media release, readouts for immunogenicity expected in patients with advanced malignancies in H2 2017.
- 05 Apr 2017 According to an Agenus Inc. media release, the first patient has been dosed in this trial.